A review on novel approaches for colon targeted drug delivery systems

Singh, Chandan Kumar; Saxena, Sumedha; Yadav, Mukesh; Samson, Alex Laurel

doi:10.29161/pt.v6.i7.2018.11

Cited by 17 publications

(10 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The result of these movements is an increase in the luminal pressure. Studies have taken advantage of such an increase in the luminal pressure in the development of pressure-controlled colon-targeted drug delivery [59].…”

Section: Pressure-controlled Delivery Systemmentioning

confidence: 99%

A Review on Development of Colon Targeted Drug Delivery System

MUHAMMED,

MOHAMMED,

VISHT

et al. 2024

Int J App Pharm

View full text Add to dashboard Cite

The purpose of this review was to select a promising drug delivery system for colon diseases. This review covers the development of Colon Targeted Drug Delivery System (CTDDS) using 36 y (1986-2022) data from various research and review articles. All fig. designed using by BioRender website. vThe colon-targeted drug delivery systems developed for the specific site drug delivery which applied for both local and systemic actions of the drug; since the drug targeted to be release within the colon, the unwanted systemic side effects are reduced along with it. Systemic side effects include organ damage, respiratory diseases and, cardiovascular damage and other illnesses. Colon-targeted drug delivery system used in the treatment of diseases in the colon, including ulcerative colitis, irritable bowel syndrome and colorectal cancer. The benefit of colon-targeted drug delivery besides the reduction of side effects also include protection from premature drug release or burst in the stomach or small intestine before reaching the colon. For the development of drugs with such benefits and advantages, drug delivery systems and approaches have used for Colon targeted drug delivery systems, varying from conventional colon-targeting drug delivery systems to novel approaches for Colon-targeted drug delivery systems. Conventional drug delivery includes the use of prodrugs, pH-dependent, time-dependent, matrix-based systems, polysaccharides-derived systems, and bio-adhesive system while novel approaches include types such as port system, pulsincap system, pressure-controlled system, osmotic controlled system, CODES, and the newest approach wish is the use of nanotechnology in colon targeted drug delivery. In this research both techniques reviewed, and their types discussed as well. The limitation of their uses and the advantage of each system discussed with a breakdown of the different mechanisms used to formulate such systems. A successful colon targeting delivery can release the drug to a specific segment in colon due to presence of different colonic enzymes formed by microorganisms that metabolize drug carrier linkage. Use of combined approaches i.e., conventional systems and newer approaches may be the best way to cure colon diseases using an optimized colon drug delivery system.

show abstract

Section: Pressure-controlled Delivery Systemmentioning

confidence: 99%

A Review on Development of Colon Targeted Drug Delivery System

MUHAMMED,

MOHAMMED,

VISHT

et al. 2024

Int J App Pharm

View full text Add to dashboard Cite

show abstract

“…Drug delivery to the colon can be accomplished using the same drug molecules that are used to treat GIT diseases. In the context of pharmaceutical factors, the colonic stay of drugs affects the drug absorption and thus for the low absorbed drugs colon provide more stay time and hence high absorption (Singh N and Khanna 2012 ). Therefore, such parameters should be considered for the delivery systems targeting colon.…”

Section: Barriers/challenges In Successful Therapy Of Ulcerative Colitismentioning

confidence: 99%

Responsive nanosystems for targeted therapy of ulcerative colitis: Current practices and future perspectives

et al. 2023

View full text Add to dashboard Cite

The pharmacological approach to treating gastrointestinal diseases is suffering from various challenges. Among such gastrointestinal diseases, ulcerative colitis manifests inflammation at the colon site specifically. Patients suffering from ulcerative colitis notably exhibit thin mucus layers that offer increased permeability for the attacking pathogens. In the majority of ulcerative colitis patients, the conventional treatment options fail in controlling the symptoms of the disease leading to distressing effects on the quality of life. Such a scenario is due to the failure of conventional therapies to target the loaded moiety into specific diseased sites in the colon. Targeted carriers are needed to address this issue and enhance the drug effects. Conventional nanocarriers are mostly readily cleared and have nonspecific targeting. To accumulate the desired concentration of the therapeutic candidates at the inflamed area of the colon, smart nanomaterials with responsive nature have been explored recently that include pH responsive, reactive oxygen species responsive (ROS), enzyme responsive and thermo – responsive smart nanocarrier systems. The formulation of such responsive smart nanocarriers from nanotechnology scaffolds has resulted in the selective release of therapeutic drugs, avoiding systemic absorption and limiting the undesired delivery of targeting drugs into healthy tissues. Recent advancements in the field of responsive nanocarrier systems have resulted in the fabrication of multi-responsive systems i.e. dual responsive nanocarriers and derivitization that has increased the biological tissues and smart nanocarrier’s interaction. In addition, it has also led to efficient targeting and significant cellular uptake of the therapeutic moieties. Herein, we have highlighted the latest status of the responsive nanocarrier drug delivery system, its applications for on–demand delivery of drug candidates for ulcerative colitis, and the prospects are underpinned.

show abstract

“…Apart from this, other factors involved are functional group of drug molecule, chemical nature, its stability factor, constant factors like partition coefficient etc. [49][50][51][52][53]…”

Section: Drug Carriersmentioning

confidence: 99%

A Review On: Colon Targeted Drug Delivery System

Pawar¹,

Patil²,

Fegade³

2020

AJPTR

View full text Add to dashboard Cite

Colon-specific drug delivery systems (CDDS) are desirable for the treatment of a range of local diseases such as ulcerative colitis, Crohn's disease, irritable bowel syndrome, chronic pancreatitis, and colonic cancer. In addition, the colon can be a potential site for the systemic absorption of several drugs to treat non-colonic conditions. Drugs such as proteins and peptides that are known to degrade in the extreme gastric pH, if delivered to the colon intact, can be systemically absorbed by colonic mucosa. In order to achieve effective therapeutic outcomes, it is imperative that the designed delivery system specifically targets the drugs into the colon. Several formulation approaches have been explored in the development colon-targeted drug delivery systems. Colon targeting holds a great potential and still need more innovative work. This review article discusses introduction of colon, need and approaches of colonic drug delivery, factor effecting colonic transition, colonic diseases and the novel and emerging technologies for colon targeting.

show abstract

A review on novel approaches for colon targeted drug delivery systems

Cited by 17 publications

References 5 publications

A Review on Development of Colon Targeted Drug Delivery System

A Review on Development of Colon Targeted Drug Delivery System

Responsive nanosystems for targeted therapy of ulcerative colitis: Current practices and future perspectives

A Review On: Colon Targeted Drug Delivery System

Contact Info

Product

Resources

About